Polaryx Therapeutics' IPO

Listed Feb 2, 2026 by a direct listing on Nasdaq as PLYX, with no offer price.

Ticker

PLYX

Breakaway does the work for you: insider and Congress trades, the chart, and the financials, in one score.

See it live, free until Wednesday morning. No account. No card. Then keep going with a free account.

From its final prospectus (424B4) on SEC EDGAR, filed Feb 2, 2026.

What does Polaryx Therapeutics do?

“We are a clinical-stage biotechnology company committed to the discovery, development, and commercialization of novel, disease-modifying therapies for rare, pediatric lysosomal storage disorders ("LSDs").”

From its final prospectus (424B4), filed Feb 2, 2026

Polaryx Therapeutics' facts, each with its source
Fact	Polaryx Therapeutics
Incorporated	Wyoming, 2014From its final prospectus (424B4) of Feb 2, 2026
Headquarters	Paramus, New JerseyFrom its final prospectus (424B4) of Feb 2, 2026
Employees	11, as of November 1, 2025From its final prospectus (424B4) of Feb 2, 2026
Website	polaryx.comFrom its final prospectus (424B4) of Feb 2, 2026

What is the offering?

Each figure names the filing it is from and that filing's date. The market cap is Breakaway's arithmetic from the prospectus's share count.

Polaryx Therapeutics' facts, each with its source
Fact	Polaryx Therapeutics
Exchange	Nasdaq Capital Market, as PLYX (applied to list)From the final prospectus (424B4) filed Feb 2, 2026

What the filing says about its money

Polaryx Therapeutics' facts, each with its source
Fact	Polaryx Therapeutics
Revenue	None from product sales yetFrom its final prospectus (424B4) of Feb 2, 2026: it has not generated any product revenue
Cash	$5.7 million, as of September 30, 2025From its final prospectus (424B4) of Feb 2, 2026: cash and cash equivalents

What risks does Polaryx Therapeutics name first?

“We have a limited operating history and have no products approved for commercial sale, and our results may vary from quarter to quarter.”
“We will require substantial additional capital to finance our operations in the future.”
“We have incurred significant losses since inception, expect to incur significant losses for the foreseeable future and may not be able to achieve or sustain profitability in the future.”

The first three of the risks its prospectus summary lists, in the company's words. The rest, and each in full, are in the filing. Read the filing.

Every date of Polaryx Therapeutics' IPO

Polaryx Therapeutics' IPO dates, each with its source
What	Day	Source
Registration filedForm S-1, SEC EDGAR	Nov 21, 2025	Form S-1, SEC EDGAR
Exchange registration filedexchange registration (Form 8-A), SEC EDGAR	Jan 27, 2026	exchange registration (Form 8-A), SEC EDGAR
Declared effective by the SECSEC notice of effectiveness, SEC EDGAR	Jan 29, 2026	SEC notice of effectiveness, SEC EDGAR
Pricedfinal prospectus (424B4), SEC EDGAR	Feb 2, 2026	final prospectus (424B4), SEC EDGAR
First tradeMassive's IPO calendar	Feb 2, 2026	Massive's IPO calendar
Lock-upNo lock-up period read from its prospectus	Not read	No lock-up period read from its prospectus

How did its first days trade?

From its daily bars, each close against its first open.

Polaryx Therapeutics' first sessions
Day	Open	Close
Feb 2	$45	$35
Feb 3	$33.90	$21.95
Feb 4	$18.31	$22.50
Feb 5	$19.99	$16
Feb 6	$17.20	$8.91

The other IPOs expected

The other IPOs expected or in registration
Company	Price	Market cap	Expected
OPAYNYSE: OPAY · No day yet	$19 to $21	Not yet	No day yetexchange registration Oct 26
Georgia BankingNasdaq: GBC · No day yet	Direct	Not yet	No day yetexchange registration Oct 21
Aspen NeuroscienceNasdaq: ASPE · No day yet	$15 to $17About $465M	$465Mat the midpoint	No day yetterms set Oct 26
Bambusa TherapeuticsNasdaq: BBTX · No day yet	$15 to $17About $796M	$796Mat the midpoint	No day yetterms set Oct 26
BitariNasdaq: BIAI · No day yet	$7About $302M	$302Mat the midpoint	No day yetterms set Oct 26
LIS TechnologiesNasdaq · No day yet	$5 to $7	Not yet	No day yetterms set Oct 26

Polaryx Therapeutics IPO questions

When is Polaryx Therapeutics' IPO?

Listed Feb 2, 2026 by a direct listing on Nasdaq as PLYX, with no offer price.

What is Polaryx Therapeutics' IPO price?

Polaryx Therapeutics lists directly: there is no offer price, and its first price is set by the exchange's opening auction.

Does Breakaway rate Polaryx Therapeutics?

Breakaway scores a new stock from its second trading day, ranked against every US stock it scores. For its first 21 sessions the page says New listing in place of the tier, and each check that needs more history waits for it.

Can Breakaway say where Polaryx Therapeutics' price will go?

No. Breakaway does not say where a price will go. Every figure here is from the company's SEC filings, linked on each line.

Where every figure comes from.

Each company's SEC filings on EDGAR, read twice a day: its registration (Form S-1 or F-1), the amendment that sets its price range, and its final prospectus (424B4). The shares, the price, the underwriters, the lock-up, and the company's words are the filing's, linked on each line.
The expected day is Massive's IPO calendar's, the first trade the market data's, and the moves each stock's daily closes against its offer price.
The market cap is Breakaway's arithmetic: the shares the prospectus says will be outstanding after the offering, times the midpoint of the range or the offer price.
The Quality Score is Breakaway's, from a stock's second trading day; for its first 21 sessions it is marked New listing, and each check that needs more history waits for it.
Blank-check companies (SPACs) and unit offerings are left out and counted; a direct listing and a US listing of a company listed abroad are in and marked.

We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.

Every new listing, ranked live, free. No account.

See all 16 new listings ranked

See it live, free until Wednesday morning. No account. No card. Then keep going with a free account.

Every IPO expected and listed, and February 2026's listings.